CompletedPhase 2

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease

Lead sponsor

Memory Pharmaceuticals

Asset

MEM 1003

Listed sites

Recruiting sites

Enrollment

183

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MMSE 10-24

Primary endpoint

•Cognitive function

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDMEM 1003-004

NCT IDNCT00257673

Timeline

Milestones

Study start2005-11 (month precision)

Study first posted2005-11-23estimated

Primary completion2007-10actual (month precision)

Study completion2007-10actual (month precision)

Last update posted2008-05-06estimated

Assets

Drug assets

MEM 1003

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•standardized MMSE Score of 10 to 24 points

•diagnosis of probable Alzheimer's disease

•magnetic resonance imaging or computed tomography examination compatible with AD

•modified Hachinski Ischemia Score of less than or equal to 4

•currently receiving no AD therapy or currently receiving donepezil, rivastigmine, or galantamine

Exclusion criteria

•head injury associated with cognitive impairment

•history of vascular dementia stroke, transient cerebral ischemic episodes, major depression, major psychotic disorder, or symptomatic postural hypotension

•treatment for Alzheimer's disease other than donepezil, rivastigmine, or galantamine; tacrine is not permitted in the last 30 days or memantine in the last 90 days

•treatment with calcium channel blockers or any investigational medications within the prior 30 days

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Function / daily living

Global cognition

1 endpoint

Primary/protocol endpoint

Cognitive function

Time frame:Change from baseline at wk 12

descriptive

Function / daily living

1 endpoint

Secondary/protocol endpoint

Other Cognitive Assessments, activities of daily living, functional assessments and safety

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.